Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite new data on efficacy and resistance during long-term nucleos(t)ide analogue therapy for the treatment of chronic HBV infection
- Describe the latest findings on adverse events associated with the use of nucleos(t)ide analogues and their safety in the settings of pregnancy and liver cirrhosis
- Discuss the relationship between on-treatment HBsAg decline and serologic response during telbivudine therapy
- Summarize recent data on the sustained efficacy of long-term adefovir therapy during prolonged posttreatment follow-up
Topics covered include:
- Resistance Through 6 Years of Entecavir Treatment
- Safety and Efficacy of 3 Years of Telbivudine Therapy in Patients Without Evidence of Genotypic Resistance at Year 2
- Kinetics of HBsAg Reduction With Telbivudine Treatment in HBeAg-Positive Patients
- 5-Year Posttreatment Follow-up of HBeAg-Negative Patients After 4-5 Years of Adefovir Therapy
- Safety and Efficacy of Tenofovir Therapy in Patients With Cirrhosis
- Tenofovir vs Tenofovir/Emtricitabine in Patients With Persistent Viremia During Adefovir Treatment
- Prenatal Lamivudine or Tenofovir Exposure and Risk of Birth Defects
Abstract